Autocrine-inhibitory LHRH Loop Prostate Cancer Cell Line DU 145: Evidence for an Hormone (LHRH) Agonists on Human Androgen-independent Antiproliferative Effects of Luteinizing Hormone-releasing

نویسندگان

  • Donatella Dondi
  • Patrizia Limonta
  • Roberta M. Moretti
چکیده

The therapeutic options for the treatment of androgea-independent prostatic cancers are rather limited; this Is mainly because our under standing of the local mechanisms involved In the control of androgen independent proliferation of the tumor is stlH very poor. The present experlmeats have been performed to verify whether luteinizing hormone releasing hormone (LHRH) agonists may possess a direct effect on the growth of the human androgen-independeat prostate cancer cells DU 145 and whether a LHRH growth regulatory system may be present in these cells. The data have shown that two potent LHRII agonists (Zoladex and Buserelin) exert a significant and dose-dependent andproliferative action on DU 145 cells, after 4 days of treatment. The inhibitory action of Zoladex and Buserelin is completely counteracted by the simultaneous treatment of the cells with a potent LHRH antagonist, suggesting that the action of the LHRH agoaists may be mediated by specific receptors. This hypothesis has been confirmed by the demonstration that low-affinity binding sites for lasI@Buserelin are present on DU 145 cell membranes, particularly when cells are cultured in serum-free conditions. By using the reverse transcriptlon-polymerase chala reaction technique, in the pros eace of a pair of specificollgonucleotldeprimerscomplementaryto the human LHRH complementary DNA, it has been demonstrated that a mRNA for LHRH Is expressed In DU 145 cells. Taken together, these data seem to indicate that an autocrine/paracrine LHRH (or UIRH-llke) loop is present in androgea-independent prostate cancer cells, and may par ticipate in the regulation of tumor cell growth. To verify this hypothesis, DU145cellshavebeenculturedinserum-freeconditions, andtreatedwith a LHRHantagonistfor 4 days. The treatmentresultedin a significant increase of cell proliferation, suggesting an inhibitory role for the LHRH system in the local regulation of cell growth. In conclusion, these data demonstrate that: (a) LHRH agonists exert a specific antiproilferative action on the human androgen-independent DU 145 calls; (b) an autocrine/paracrine LHRH (or LIIRH.like) loop, which seems to be Inhibitory on cell proliferation, is expressed in DU 145 cells.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop.

The therapeutic options for the treatment of androgen-independent prostatic cancers are rather limited; this is mainly because our understanding of the local mechanisms involved in the control of androgen-independent proliferation of the tumor is still very poor. The present experiments have been performed to verify whether luteinizing hormone-releasing hormone (LHRH) agonists may possess a dir...

متن کامل

Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling.

PURPOSE Advanced prostate cancer is treated initially by central suppression of androgen production by luteinizing hormone-releasing hormone (LHRH) agonists. Intriguingly, even hormone-independent cancers often show some, if only slight, growth retardation when these agonists are delivered in pharmacological doses. Previous studies have shown in cell lines and animal xenograft models that activ...

متن کامل

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels

Management of castration-resistant prostate cancer (CRPC) is challenging due to lack of efficacious therapy. Luteinizing hormone-releasing hormone analogs appear to act directly on cells based on the LHRH receptors on human prostate adenocarcinoma cells. We explored anticancer activity of a cytotoxic analog of LHRH, AEZS-108 consisting of LHRH agonist linked to doxorubicin. Nude mice bearing DU...

متن کامل

An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix is a third generation antagonist of luteinizing hormone-releasing hormone (LHRH, also termed gona...

متن کامل

A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer

LHRH receptor, is over-expressed in a variety of human tumors and, is a potential binding site for targeted metastatic prostate cancer therapy. The objectives of our study were to synthesize a bioconjugate of the LHRH analog [DLys6]-LHRH and the anti-tumor agent methotrexate and test the hypothesis that [DLys6]-LHRH-MTX targets and inhibits prostate cancer cell growth in vitro and in vivo. The ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2006